Optimizing treatment for metastatic renal cell carcinoma

Jean Jacques Patard, Camillo Porta, John Wagstaff, Juergen E. Gschwend

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

With the advent of targeted antiangiogenic therapies for renal cell carcinoma (RCC), the prognosis for patients with locally advanced or metastatic disease has significantly improved. Indeed, the results of several randomized clinical trials have demonstrated that targeted therapies, such as tyrosine kinase inhibitors (TKIs), provide superior efficacy and tolerability compared with traditional cytokine-based treatments. However, TKI therapy is still associated with significant toxicities related to off-target inhibition that are detrimental to patient quality of life. The results of ongoing head-to-head trials will determine how these agents compare with each other in terms of efficacy, and whether TKIs that interact with fewer off-target kinases have improved tolerability profiles. Furthermore, examining how these agents could be integrated with surgery to provide a multimodal approach to the treatment of metastatic RCC could further improve the outlook for RCC patients.

Original languageEnglish
Pages (from-to)1901-1911
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume11
Issue number12
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Renal Cell Carcinoma
Protein-Tyrosine Kinases
Therapeutics
Phosphotransferases
Randomized Controlled Trials
Quality of Life
Cytokines

Keywords

  • neoadjuvant therapy
  • renal cell carcinoma
  • tyrosine kinase inhibitor
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Patard, J. J., Porta, C., Wagstaff, J., & Gschwend, J. E. (2011). Optimizing treatment for metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 11(12), 1901-1911. https://doi.org/10.1586/era.11.177

Optimizing treatment for metastatic renal cell carcinoma. / Patard, Jean Jacques; Porta, Camillo; Wagstaff, John; Gschwend, Juergen E.

In: Expert Review of Anticancer Therapy, Vol. 11, No. 12, 12.2011, p. 1901-1911.

Research output: Contribution to journalArticle

Patard, JJ, Porta, C, Wagstaff, J & Gschwend, JE 2011, 'Optimizing treatment for metastatic renal cell carcinoma', Expert Review of Anticancer Therapy, vol. 11, no. 12, pp. 1901-1911. https://doi.org/10.1586/era.11.177
Patard, Jean Jacques ; Porta, Camillo ; Wagstaff, John ; Gschwend, Juergen E. / Optimizing treatment for metastatic renal cell carcinoma. In: Expert Review of Anticancer Therapy. 2011 ; Vol. 11, No. 12. pp. 1901-1911.
@article{c4978ff551b84b62b34e89f9071067df,
title = "Optimizing treatment for metastatic renal cell carcinoma",
abstract = "With the advent of targeted antiangiogenic therapies for renal cell carcinoma (RCC), the prognosis for patients with locally advanced or metastatic disease has significantly improved. Indeed, the results of several randomized clinical trials have demonstrated that targeted therapies, such as tyrosine kinase inhibitors (TKIs), provide superior efficacy and tolerability compared with traditional cytokine-based treatments. However, TKI therapy is still associated with significant toxicities related to off-target inhibition that are detrimental to patient quality of life. The results of ongoing head-to-head trials will determine how these agents compare with each other in terms of efficacy, and whether TKIs that interact with fewer off-target kinases have improved tolerability profiles. Furthermore, examining how these agents could be integrated with surgery to provide a multimodal approach to the treatment of metastatic RCC could further improve the outlook for RCC patients.",
keywords = "neoadjuvant therapy, renal cell carcinoma, tyrosine kinase inhibitor, vascular endothelial growth factor",
author = "Patard, {Jean Jacques} and Camillo Porta and John Wagstaff and Gschwend, {Juergen E.}",
year = "2011",
month = "12",
doi = "10.1586/era.11.177",
language = "English",
volume = "11",
pages = "1901--1911",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Optimizing treatment for metastatic renal cell carcinoma

AU - Patard, Jean Jacques

AU - Porta, Camillo

AU - Wagstaff, John

AU - Gschwend, Juergen E.

PY - 2011/12

Y1 - 2011/12

N2 - With the advent of targeted antiangiogenic therapies for renal cell carcinoma (RCC), the prognosis for patients with locally advanced or metastatic disease has significantly improved. Indeed, the results of several randomized clinical trials have demonstrated that targeted therapies, such as tyrosine kinase inhibitors (TKIs), provide superior efficacy and tolerability compared with traditional cytokine-based treatments. However, TKI therapy is still associated with significant toxicities related to off-target inhibition that are detrimental to patient quality of life. The results of ongoing head-to-head trials will determine how these agents compare with each other in terms of efficacy, and whether TKIs that interact with fewer off-target kinases have improved tolerability profiles. Furthermore, examining how these agents could be integrated with surgery to provide a multimodal approach to the treatment of metastatic RCC could further improve the outlook for RCC patients.

AB - With the advent of targeted antiangiogenic therapies for renal cell carcinoma (RCC), the prognosis for patients with locally advanced or metastatic disease has significantly improved. Indeed, the results of several randomized clinical trials have demonstrated that targeted therapies, such as tyrosine kinase inhibitors (TKIs), provide superior efficacy and tolerability compared with traditional cytokine-based treatments. However, TKI therapy is still associated with significant toxicities related to off-target inhibition that are detrimental to patient quality of life. The results of ongoing head-to-head trials will determine how these agents compare with each other in terms of efficacy, and whether TKIs that interact with fewer off-target kinases have improved tolerability profiles. Furthermore, examining how these agents could be integrated with surgery to provide a multimodal approach to the treatment of metastatic RCC could further improve the outlook for RCC patients.

KW - neoadjuvant therapy

KW - renal cell carcinoma

KW - tyrosine kinase inhibitor

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=82355171772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82355171772&partnerID=8YFLogxK

U2 - 10.1586/era.11.177

DO - 10.1586/era.11.177

M3 - Article

C2 - 22117157

AN - SCOPUS:82355171772

VL - 11

SP - 1901

EP - 1911

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 12

ER -